These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 20538289)

  • 1. Celecoxib combined with atorvastatin prevents progression of atherosclerosis.
    Raval M; Frank PG; Laury-Kleintop L; Yan G; Lanza-Jacoby S
    J Surg Res; 2010 Oct; 163(2):e113-22. PubMed ID: 20538289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The select cyclooxygenase-2 inhibitor celecoxib reduced the extent of atherosclerosis in apo E-/- mice.
    Jacob S; Laury-Kleintop L; Lanza-Jacoby S
    J Surg Res; 2008 May; 146(1):135-42. PubMed ID: 17950326
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemoprevention of familial adenomatous polyposis by low doses of atorvastatin and celecoxib given individually and in combination to APCMin mice.
    Swamy MV; Patlolla JM; Steele VE; Kopelovich L; Reddy BS; Rao CV
    Cancer Res; 2006 Jul; 66(14):7370-7. PubMed ID: 16849589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Statin therapy alone and in combination with an acyl-CoA:cholesterol O-acyltransferase inhibitor on experimental atherosclerosis.
    Worthley SG; Helft G; Corti R; Worthley MI; Chew DP; Fayad ZA; Zaman AG; Fallon JT; Fuster V; Badimon JJ
    Pathophysiol Haemost Thromb; 2007; 36(1):9-17. PubMed ID: 18332609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout mice.
    Nachtigal P; Pospisilova N; Jamborova G; Pospechova K; Solichova D; Andrys C; Zdansky P; Micuda S; Semecky V
    Life Sci; 2008 Mar; 82(13-14):708-17. PubMed ID: 18289605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin and celecoxib inhibit prostate PC-3 tumors in immunodeficient mice.
    Zheng X; Cui XX; Avila GE; Huang MT; Liu Y; Patel J; Kong AN; Paulino R; Shih WJ; Lin Y; Rabson AB; Reddy BS; Conney AH
    Clin Cancer Res; 2007 Sep; 13(18 Pt 1):5480-7. PubMed ID: 17875778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.
    Grothusen C; Bley S; Selle T; Luchtefeld M; Grote K; Tietge UJ; Drexler H; Schieffer B
    Atherosclerosis; 2005 Sep; 182(1):57-69. PubMed ID: 16115475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aliskiren inhibits atherosclerosis development and improves plaque stability in APOE*3Leiden.CETP transgenic mice with or without treatment with atorvastatin.
    Kühnast S; van der Hoorn JW; van den Hoek AM; Havekes LM; Liau G; Jukema JW; Princen HM
    J Hypertens; 2012 Jan; 30(1):107-16. PubMed ID: 22134386
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a poxvirus-based vaccine with a cyclooxygenase-2 inhibitor (celecoxib) elicits antitumor immunity and long-term survival in CEA.Tg/MIN mice.
    Zeytin HE; Patel AC; Rogers CJ; Canter D; Hursting SD; Schlom J; Greiner JW
    Cancer Res; 2004 May; 64(10):3668-78. PubMed ID: 15150127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MDOC and atorvastatin have potential antiinflammatory effects in vascular endothelium of apoE-/- mouse model of atherosclerosis.
    Nachtigal P; Pospisilova N; Pospechova K; Jamborova G; Kopecky M; Jaynes R; Briestensky J; Santar I; Smahelova A; Solichova D; Zdansky P; Semecky V
    Life Sci; 2006 Mar; 78(17):1983-9. PubMed ID: 16305803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Atorvastatin has distinct effects on endothelial markers in different mouse models of atherosclerosis.
    Nachtigal P; Jamborova G; Pospisilova N; Pospechova K; Solichova D; Zdansky P; Semecky V
    J Pharm Pharm Sci; 2006; 9(2):222-30. PubMed ID: 16959191
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of low dose atorvastatin versus diet-induced cholesterol lowering on atherosclerotic lesion progression and inflammation in apolipoprotein E*3-Leiden transgenic mice.
    Verschuren L; Kleemann R; Offerman EH; Szalai AJ; Emeis SJ; Princen HM; Kooistra T
    Arterioscler Thromb Vasc Biol; 2005 Jan; 25(1):161-7. PubMed ID: 15514207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hyperexpression of cyclooxygenase 2 in the lupus immune system and effect of cyclooxygenase 2 inhibitor diet therapy in a murine model of systemic lupus erythematosus.
    Zhang L; Bertucci AM; Smith KA; Xu L; Datta SK
    Arthritis Rheum; 2007 Dec; 56(12):4132-41. PubMed ID: 18050205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Statins inhibit cyclooxygenase-2 and matrix metalloproteinase-9 in human endothelial cells: anti-angiogenic actions possibly contributing to plaque stability.
    Massaro M; Zampolli A; Scoditti E; Carluccio MA; Storelli C; Distante A; De Caterina R
    Cardiovasc Res; 2010 May; 86(2):311-20. PubMed ID: 19946014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First head-to-head study comparing rosuvastatin and atorvastatin effects on the treatment of atherosclerosis.
    Cardiovasc J Afr; 2008; 19(1):60. PubMed ID: 18320096
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-atherosclerotic effect of atorvastatin and clopidogrel alone and in combination in rats.
    Srinivas M; Annapurna A; Reddy YN
    Indian J Exp Biol; 2008 Oct; 46(10):698-703. PubMed ID: 19024167
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory effect of co-administration of atorvastatin and endothelin-1 receptor antagonist on the progression of atherosclerosis in rabbit.
    Sun Y; Liu J; Yang B; Sai X; Li T; Wang D; Zhou R
    APMIS; 2014 Jun; 122(6):556-64. PubMed ID: 24164644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice.
    Berbée JF; Wong MC; Wang Y; van der Hoorn JW; Khedoe PP; van Klinken JB; Mol IM; Hiemstra PS; Tsikas D; Romijn JA; Havekes LM; Princen HM; Rensen PC
    J Nutr Biochem; 2013 Aug; 24(8):1423-30. PubMed ID: 23337345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of intensive atorvastatin therapy on prostaglandin E2 levels and metalloproteinase-9 activity in the plasma of patients with non-ST-elevation acute coronary syndrome.
    Gómez-Hernández A; Sánchez-Galán E; Ortego M; Martín-Ventura JL; Blanco-Colio LM; Tarín-Vicente N; Jiménez-Nacher JJ; López-Bescos L; Egido J; Tuñón J
    Am J Cardiol; 2008 Jul; 102(1):12-8. PubMed ID: 18572029
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment with ezetimibe plus low-dose atorvastatin compared with higher-dose atorvastatin alone: is sufficient cholesterol-lowering enough to inhibit platelets?
    Piorkowski M; Fischer S; Stellbaum C; Jaster M; Martus P; Morguet AJ; Schultheiss HP; Rauch U
    J Am Coll Cardiol; 2007 Mar; 49(10):1035-42. PubMed ID: 17349882
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.